Reinventing HCV Treatment: Past and Future Perspectives

被引：20

作者：

Carter, Wendy ^{[1
]}

Connelly, Sarah ^{[1
]}

Struble, Kimberly ^{[1
]}

机构：

[1] Div Antiviral Prod, 10903 New Hampshire Ave,White Oak Bldg 22,, Silver Spring, MD 20993 USA

来源：

JOURNAL OF CLINICAL PHARMACOLOGY | 2017年 / 57卷 / 03期

关键词：

hepatitis C; direct-acting antivirals; genotype; sustained virologic response; resistance-associated variants; HEPATITIS-C VIRUS; SUSTAINED VIROLOGICAL RESPONSE; ALL-CAUSE MORTALITY; UNITED-STATES; ANTIVIRAL THERAPY; VIRAL-HEPATITIS; PREVALENCE; RESISTANCE; INTERFERON-ALPHA-2B; INFECTION;

D O I：

10.1002/jcph.830

中图分类号：

R9 [药学];

学科分类号：

1007 ;

摘要：

This review paper summarizes the epidemiology of hepatitis C virus (HCV) and chronic HCV infection, including HCV virology and treatment regimens. Specifically, we focus on the evolution of past, current, and future HCV treatment options, the reasons for treatment failure, and the impact of resistanceassociated variants on treatment success.

引用

页码：287 / 296

页数：10